Y Intercept Hong Kong Ltd Takes Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Y Intercept Hong Kong Ltd purchased a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 27,836 shares of the biopharmaceutical company's stock, valued at approximately $581,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. abrdn plc bought a new stake in Catalyst Pharmaceuticals in the 4th quarter valued at about $10,115,000. Jane Street Group LLC increased its holdings in shares of Catalyst Pharmaceuticals by 245.4% during the third quarter. Jane Street Group LLC now owns 401,908 shares of the biopharmaceutical company's stock valued at $7,990,000 after acquiring an additional 285,564 shares in the last quarter. Walleye Capital LLC acquired a new position in shares of Catalyst Pharmaceuticals during the third quarter worth approximately $4,936,000. Pacer Advisors Inc. lifted its holdings in shares of Catalyst Pharmaceuticals by 5.4% in the 4th quarter. Pacer Advisors Inc. now owns 2,955,508 shares of the biopharmaceutical company's stock worth $61,681,000 after purchasing an additional 151,495 shares in the last quarter. Finally, Barclays PLC grew its position in Catalyst Pharmaceuticals by 129.4% in the 3rd quarter. Barclays PLC now owns 248,458 shares of the biopharmaceutical company's stock valued at $4,939,000 after purchasing an additional 140,129 shares during the period. 79.22% of the stock is currently owned by institutional investors.

Catalyst Pharmaceuticals Stock Performance

CPRX traded down $0.21 during midday trading on Wednesday, reaching $21.89. The company had a trading volume of 993,208 shares, compared to its average volume of 1,271,383. Catalyst Pharmaceuticals, Inc. has a 12-month low of $14.47 and a 12-month high of $24.64. The business has a 50-day moving average price of $22.27 and a two-hundred day moving average price of $21.49. The stock has a market cap of $2.66 billion, a PE ratio of 18.55, a P/E/G ratio of 3.31 and a beta of 0.80.

Remove Ads

Analysts Set New Price Targets

CPRX has been the topic of several research reports. Robert W. Baird upped their price objective on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a report on Monday. HC Wainwright reiterated a "buy" rating and set a $35.00 price target on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. StockNews.com raised Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, February 28th. Stephens restated an "overweight" rating and issued a $33.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. Finally, Bank of America reissued a "buy" rating and issued a $30.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Eight equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $32.50.

Insider Activity at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 62,975 shares of the business's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the sale, the insider now directly owns 188,564 shares in the company, valued at $4,333,200.72. The trade was a 25.04 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Steve Miller sold 50,000 shares of the company's stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total value of $1,096,500.00. Following the transaction, the insider now directly owns 686,996 shares in the company, valued at $15,065,822.28. This represents a 6.78 % decrease in their position. The disclosure for this sale can be found here. 11.00% of the stock is owned by company insiders.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.